03170nam a22003257a 4500
210719s20212021 xxu||||| |||| 00| 0 eng d
1663-9812
10.3389/fphar.2021.669362 [doi]
669362 [pii]
PMC8193734 [pmc]
Ovid MEDLINE(R)
34122090
Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial.
Frontiers in Pharmacology. 12:669362, 2021.
Front Pharmacol. 12:669362, 2021.
Frontiers in pharmacology
2021
FY2021
epublish
2021-07-19
Background: Coronavirus disease-2019 (COVID-19) has a wide range of pathophysiological effects. Curcumin, an active constituent of Curcuma longa (turmeric), has several properties, including anti-inflammatory, antioxidant, antiviral, anti-thrombotic, and anti-proliferative effects, which make it a promising candidate for the symptomatic treatment of COVID-19. Objective: We aimed to determine the effects of curcumin administered with piperine (to optimize absorption) on symptoms in patients with COVID-19 in a double-blind, randomized, controlled trial at a 30-bed dedicated COVID Health Center (DCHC) in Maharashtra, India. Methods: In addition to conventional COVID-19 treatment, patients in the control group received a dose of probiotics twice a day, and patients in the study group received curcumin (525 mg) with piperine (2.5 mg) in tablet form twice a day. The effects of curcumin/piperine treatment on primary and secondary outcomes were assessed for the duration of hospitalization. Results: Patients with mild, moderate, and severe symptoms who received curcumin/piperine treatment showed early symptomatic recovery (fever, cough, sore throat, and breathlessness), less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to patients of the control group. Furthermore, curcumin/piperine treatment appeared to reduce the duration of hospitalization in patients with moderate to severe symptoms, and fewer deaths were observed in the curcumin/piperine treatment group. Conclusions: Administration of oral curcumin with piperine as an adjuvant symptomatic therapy in COVID-19 treatment could substantially reduce morbidity and mortality, and ease the logistical and supply-related burdens on the healthcare system. Curcumin could be a safe and natural therapeutic option to prevent Post-Covid thromboembolic events. Clinicaltrials.gov identifier: CTRI/2020/05/025482. Copyright (c) 2021 Pawar, Mastud, Pawar, Pawar, Bhoite, Bhoite, Kulkarni and Deshpande.
English
IN PROCESS -- NOT YET INDEXED
MedStar Good Samaritan Hospital
Journal Article
Bhoite, Rahul R
Bhoite RR, Bhoite RR, Deshpande AR, Kulkarni MV, Mastud RN, Pawar KS, Pawar SK, Pawar SS
https://dx.doi.org/10.3389/fphar.2021.669362
https://dx.doi.org/10.3389/fphar.2021.669362
ART
Article
0
0
0
0
Article
authcat
authcat
2021-07-19
0
34122090
34122090
2021-07-19
2021-07-19
ART
6647
6647